Haemonetics Corporation (HAE) Launches PerQseal Elite, Advancing Minimally Invasive Vascular Care

In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. Haemonetics Corporation is one of them.

Haemonetics Corporation (NYSE:HAE), a global leader in blood and plasma management technologies, continues to advance healthcare efficiency through innovative medical devices.

In 2025, the company launched the PerQseal Elite vascular closure system, receiving European CE Mark approval. This fully bioresorbable, sutureless device is designed for large-bore vascular access sites commonly used in procedures such as transcatheter aortic valve replacement (TAVR) and endovascular aneurysm repair (EVAR). The PerQseal Elite deploys from inside the vessel without leaving residual materials like collagen or metal implants, restoring the vessel to its natural state while improving procedural control. This launch highlights the industry trend toward minimally invasive, bioresorbable devices that enhance patient outcomes and procedural efficiency.

Haemonetics Corporation (NYSE:HAE) released its first-quarter fiscal 2026 results on August 7, 2025. The business reported an earnings per share (EPS) of $1.10, beating analyst estimates by $0.09, while revenue declined 4.4% year-over-year to $321.39 million. Despite the revenue dip, the business demonstrated resilience in profitability and operational performance, highlighting its ability to navigate challenging market conditions.

In early 2025, Haemonetics Corporation (NYSE:HAE) reinforced its leadership team with strategic appointments. Frank Chan, Ph.D., was named Executive Vice President and Chief Operating Officer, overseeing research and development, regulatory affairs, manufacturing, and supply chain. Roy Galvin was appointed Executive Vice President and Chief Commercial Officer, leading global commercialization initiatives. These changes reflect the company’s focus on strengthening operational excellence and expanding its commercial reach.

While we acknowledge the potential of HAE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.